Implications of telomerase reverse transcriptase in tumor metastasis

키워드

참고문헌 (95)

1. Finkel T, "The common biology of cancer and ageing", Nature, 448, pp.767~774 (2007)
2. Palm W, "How shelterin protects mammalian telomeres", Annu Rev Genet, 42, pp.301~334 (2008)
3. Arndt GM, "New prospects for targeting telomerase beyond the telomere", Nat Rev Cancer, 16, pp.508~524 (2016)
4. Yi X, "Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels", Mol Cell Biol, 19, pp.3989~3997 (1999)
5. Cong Y, "Actions of human telomerase beyond telomeres", Cell Res, 18, pp.725~732 (2008)
6. Cong YS, "Human telomerase and its regulation", Microbiol Mol Biol Rev, 66, pp.407~425 (2002)
7. Lambert AW, "Emerging Biological Principles of Metastasis", Cell, 168, pp.670~691 (2017)
8. Wan L, "Tumor metastasis : moving new biological insights into the clinic", Nat Med, 19, pp.1450~1464 (2013)
9. Hanahan D, "Hallmarks of cancer : the next generation", Cell, 144, pp.646~674 (2011)
10. Park YJ, "Human telomerase reverse transcriptase is a promising target for cancer inhibition in squamous cell carcinomas", Anticancer Res, 34, pp.6389~6395 (2014)
11. Ding D, "Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NFkappaB-dependent transcription", FASEB J, 27, pp.4375~4383 (2013)
12. Ghosh A, "Telomerase directly regulates NF-kappaB-dependent transcription", Nat Cell Biol, 14, pp.1270~1281 (2012)
13. Taniguchi K, "NF-kappaB, inflammation, immunity and cancer : coming of age", Nat Rev Immunol, 18, pp.309~324 (2018)
14. Sullivan NJ, "Interleukin-6induces an epithelial-mesenchymal transition phenotype in human breast cancer cells", Oncogene, 28, pp.2940~2947 (2009)
15. Chuang MJ, "Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells", Cancer Sci, 99, pp.905~913 (2008)
16. Chua HL, "NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells : potential involvement of ZEB-1 and ZEB-2", Oncogene, 26, pp.711~724 (2007)
17. Pastushenko I, "EMT Transition States during Tumor Progression and Metastasis", Trends Cell Biol, 29, pp.212~226 (2019)
18. Thiery JP, "Epithelial-mesenchymal transitions in development and disease", Cell, 139, pp.871~890 (2009)
19. Tam WL, "The epigenetics of epithelial-mesenchymal plasticity in cancer", Nat Med, 19, pp.1438~1449 (2013)
20. Liu Z, "Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells", Oncogene, 32, pp.4203~4213 (2013)
21. Vlodavsky I, "Heparanase : structure, biological functions, and inhibition by heparinderived mimetics of heparan sulfate", Curr Pharm Des, 13, pp.2057~2073 (2007)
22. Park YJ, "Human telomerase reverse transcriptase(hTERT)promotes cancer invasion by modulating cathepsin D via early growth response(EGR)-1", Cancer Lett, 370, pp.222~231 (2016)
23. Tang B, "Human telomerase reverse transcriptase(hTERT)promotes gastric cancer invasion through cooperating with c-Myc to upregulate heparanase expression", Oncotarget, 7, pp.11364~11379 (2016)
24. Gocheva V, "Distinct roles for cysteine cathepsin genes in multistage tumorigenesis", Genes Dev, 20, pp.543~556 (2006)
25. Turk V, "Cysteine cathepsins : from structure, function and regulation to new frontiers", Biochim Biophys Acta, 1824, pp.68~88 (2012)
26. Hu C, "hTERT promotes the invasion of gastric cancer cells by enhancing FOXO3a ubiquitination and subsequent ITGB1 upregulation", Gut, 66, pp.31~42 (2017)
27. He B, "hTERT mediates gastric cancer metastasis partially through the indirect targeting of ITGB1 by microRNA-29a", Sci Rep, 6, pp.21955~ (2016)
28. Chen MB, "Elucidation of the Roles of Tumor Integrin beta1 in the Extravasation Stage of the Metastasis Cascade", Cancer Res, 76, pp.2513~2524 (2016)
29. Xu Z, "Integrin beta1 is a critical effector in promoting metastasis and chemo-resistance of esophageal squamous cell carcinoma", Am J Cancer Res, 7, pp.531~542 (2017)
30. Chen S, "Human telomerase reverse transcriptase recruits the beta-catenin", TCF-4 complex to transactivate chemokine(C-C motif)ligand 2 expression in colorectal cancer, 2019, pp.112, 108700~
31. Kitamura T, "Immune cell promotion of metastasis", Nat Rev Immunol, 15, pp.73~86 (2015)
32. Peinado H, "Pre-metastatic niches : organ-specific homes for metastases", Nat Rev Cancer, 17, pp.302~317 (2017)
33. Dirat B, "Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion", Cancer Res, 71, pp.2455~2465 (2011)
34. Karnoub AE, "Mesenchymal stem cells within tumour stroma promote breast cancer metastasis", Nature, 449, pp.557~563 (2007)
35. Wyckoff J, "A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors", Cancer Res, 64, pp.7022~7029 (2004)
36. Obenauf AC, "Surviving at a Distance : Organ-Specific Metastasis", Trends Cancer, 1, pp.76~91 (2015)
37. Zhou L, "Telomerase reverse transcriptase activates the expression of vascular endothelial growth factor independent of telomerase activity", Biochem Biophys Res Commun, 386, pp.739~743 (2009)
38. Liu N, "hTERT promotes tumor angiogenesis by activating VEGF via interactions with the Sp1 transcription factor", Nucleic Acids Res, 44, pp.8693~8703 (2016)
39. Bermudez Y, "VEGF-and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent", Gynecol Oncol, 106, pp.526~537 (2007)
40. Zaccagnini G, "Telomerase mediates vascular endothelial growth factordependent responsiveness in a rat model of hind limb ischemia", J Biol Chem, 280, pp.14790~14798 (2005)
41. Giampieri S, "Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility", Nat Cell Biol, 11, pp.1287~1296 (2009)
42. Padua D, "TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4", Cell, 133, pp.66~77 (2008)
43. Ding Z, "Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases", Cell, 148, pp.896~907 (2012)
44. Massague J, "Metastatic colonization by circulating tumour cells", Nature, 529, pp.298~306 (2016)
45. Senft D, "Adaptive Stress Responses During Tumor Metastasis and Dormancy", Trends Cancer, 2, pp.429~442 (2016)
46. Chambers AF, "Dissemination and growth of cancer cells in metastatic sites", Nat Rev Cancer, 2, pp.563~572 (2002)
47. Senft D, "Adaptive Stress Responses During Tumor Metastasis and Dormancy", Trends Cancer, 2, pp.429~442 (2016)
48. Gorrini C, "Modulation of oxidative stress as an anticancer strategy", Nat Rev Drug Discov, 12, pp.931~947 (2013)
49. Piskounova E, "Oxidative stress inhibits distant metastasis by human melanoma cells", Nature, 527, pp.186~191 (2015)
50. Zheng Y, "Expression of beta-globin by cancer cells promotes cell survival during blood-borne dissemination", Nat Commun, 8, pp.14344~ (2017)
51. Le Gal K, "Antioxidants can increase melanoma metastasis in mice", Sci Transl Med, 7, pp.308~ (2015)
52. Ahmed S, "Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress", J Cell Sci, 121, pp.1046~1053 (2008)
53. Haendeler J, "Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage", Arterioscler Thromb Vasc Biol, 29, pp.929~935 (2009)
54. Singhapol C, "Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis", PLoS One, 8, pp.e52989~ (2013)
55. Hetz C, "The unfolded protein response : controlling cell fate decisions under ER stress and beyond", Nat Rev Mol Cell Biol, 13, pp.89~102 (2012)
56. Zhou J, "Endoplasmic reticulum stress activates telomerase", Aging Cell, 13, pp.197~200 (2014)
57. Yu M, "Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition", Science, 339, pp.580~584 (2013)
58. Valastyan S, "Tumor metastasis : molecular insights and evolving paradigms", Cell, 147, pp.275~292 (2011)
59. Huang Y, "Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis", Cancer Res, 69, pp.7529~7537 (2009)
60. Weis S, "Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis", J Cell Biol, 167, pp.223~229 (2004)
61. Gupta GP, "ID genes mediate tumor reinitiation during breast cancer lung metastasis", Proc Natl Acad Sci U S A, 104, pp.19506~19511 (2007)
62. Qian BZ, "CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis", Nature, 475, pp.222~225 (2011)
63. Pantel K, "Dissecting the metastatic cascade", Nat Rev Cancer, 4, pp.448~456 (2004)
64. Aguirre-Ghiso JA, "ERK(MAPK)activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK)", Cancer Res, 63, pp.1684~1695 (2003)
65. Yu-Lee LY, "Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFbetaRIII-p38MAPKpS249", T252RB Pathway, 2018, pp.78, 2911~2924
66. Aguirre Ghiso JA, "Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling", J Cell Biol, 147, pp.89~104 (1999)
67. Shibue T, "Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs", Proc Natl Acad Sci U S A, 106, pp.10290~10295 (2009)
68. Douma S, "Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB", Nature, 430, pp.1034~1039 (2004)
69. Kobayashi A, "Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone", J Exp Med, 208, pp.2641~2655 (2011)
70. Gao H, "The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites", Cell, 150, pp.764~779 (2012)
71. Shiozawa Y, "The bone marrow niche : habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites", Leukemia, 22, pp.941~950 (2008)
72. Zhang XH, "Latent bone metastasis in breast cancer tied to Src-dependent survival signals", Cancer Cell, 16, pp.67~78 (2009)
73. Okamoto N, "Maintenance of tumor initiating cells of defined genetic composition by nucleostemin", Proc Natl Acad Sci U S A, 108, pp.20388~20393 (2011)
74. Cassar L, "Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth", Cancer Res, 68, pp.9157~9166 (2008)
75. Li H, "Transforming growth factor beta suppresses human telomerase reverse transcriptase(hTERT)by Smad3 interactions with c-Myc and the hTERT gene", J Biol Chem, 281, pp.25588~25600 (2006)
76. Horn S, "TERT promoter mutations in familial and sporadic melanoma", Science, 339, pp.959~961 (2013)
77. Huang FW, "Highly recurrent TERT promoter mutations in human melanoma", Science, 339, pp.957~959 (2013)
78. Vinagre J, "Frequency of TERT promoter mutations in human cancers", Nat Commun, 4, pp.2185~ (2013)
79. Bell RJ, "Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer", Science, 348, pp.1036~1039 (2015)
80. Griewank KG, "TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma", J Natl Cancer Inst, 106, pp.1~13 (2014)
81. Landa I, "Frequent somatic TERT promoter mutations in thyroid cancer : higher prevalence in advanced forms of the disease", J Clin Endocrinol Metab, 98, pp.E1562~E1562 (2013)
82. Liu X, "TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer", J Clin Endocrinol Metab, 99, pp.E1130~E1136 (2014)
83. Liu R, "Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy", Endocr Relat Cancer, 21, pp.825~830 (2014)
84. Melo M, "TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas", J Clin Endocrinol Metab, 99, pp.E754~765 (2014)
85. George JR, "Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC", J Clin Endocrinol Metab, 100, pp.E1550~1559 (2015)
86. Pestana A, "TERT biology and function in cancer : beyond immortalisation", J Mol Endocrinol, 58, pp.R129~R146 (2017)
87. Wang K, "TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR", Oncotarget, 5, pp.12428~12439 (2014)
88. Liu W, "Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC", Oncotarget, 8, pp.179~190 (2017)
89. Liu R, "Regulation of mutant TERT by BRAF V600E", MAP kinase pathway through FOS, Nat Commun, pp.2018, 9[DOI]
90. Low KC, "Telomerase : central regulator of all of the hallmarks of cancer", Trends Biochem Sci, 38, pp.426~434 (2013)
91. Yuan X, "Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer : old actors and new players", Oncogene, 38, pp.6172~6183 (2019)
92. Junzhi Zhou, "Telomerase reverse transcriptase in the regulation of gene expression", BMB Reports, 47(1), pp.8~14 (2014), 생화학분자생물학회
93. Jafri MA, "Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies", Genome Med, 8, pp.69~ (2016)
94. Marian CO, "The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth", Clin Cancer Res, 16, pp.154~163 (2010)
95. Zanetti M, "A second chance for telomerase reverse transcriptase in anticancer immunotherapy", Nat Rev Clin Oncol, 14, pp.115~128 (2017)

관련 논문AI추천